Eyepoint Pharmaceuticals Correlations
| EYPT Stock | USD 16.47 1.10 6.26% |
The correlation of Eyepoint Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eyepoint Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eyepoint Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Modest diversification
The correlation between Eyepoint Pharmaceuticals and NYA is 0.27 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Eyepoint Pharmaceuticals and NYA in the same portfolio, assuming nothing else is changed.
Eyepoint |
The ability to find closely correlated positions to Eyepoint Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eyepoint Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eyepoint Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eyepoint Pharmaceuticals to buy it.
Moving against Eyepoint Stock
| 0.68 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.65 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.63 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.61 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.53 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.49 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.48 | ELYM | Eliem Therapeutics | PairCorr |
| 0.78 | ACRV | Acrivon Therapeutics Financial Report 14th of May 2024 | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Eyepoint Stock performing well and Eyepoint Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Eyepoint Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| OCUP | 2.87 | (0.91) | 0.00 | (0.57) | 0.00 | 4.35 | 21.95 | |||
| RVPH | 3.41 | (0.33) | 0.00 | 3.66 | 0.00 | 7.31 | 32.56 | |||
| PLX | 2.69 | (0.53) | 0.00 | (0.11) | 0.00 | 5.84 | 16.16 | |||
| SLS | 4.58 | 1.86 | 0.26 | 2.64 | 5.26 | 11.02 | 44.72 | |||
| DRTSW | 6.31 | 0.03 | 0.03 | 0.09 | 7.05 | 16.00 | 37.72 | |||
| HCWB | 3.36 | 0.61 | 0.15 | 1.13 | 2.89 | 8.50 | 24.78 | |||
| IPHA | 3.12 | (0.20) | 0.00 | (0.04) | 0.00 | 7.02 | 27.96 | |||
| OBIO | 3.35 | (1.10) | 0.00 | (0.39) | 0.00 | 6.15 | 19.79 | |||
| CMRX | 2.53 | 0.03 | 0.00 | 0.15 | 3.33 | 4.95 | 25.63 | |||
| DAWN | 2.97 | 0.14 | 0.07 | 0.15 | 3.39 | 6.06 | 20.03 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Eyepoint Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Analyzer Now
Idea AnalyzerAnalyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
| All Next | Launch Module |
Eyepoint Pharmaceuticals Corporate Directors
Eyepoint Pharmaceuticals corporate directors refer to members of an Eyepoint Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Eyepoint Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Eyepoint Pharmaceuticals' board members must vote for the resolution. The Eyepoint Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Douglas Godshall | Independent Director | Profile | |
| Kristine Peterson | Independent Director | Profile | |
| John Landis | Director | Profile | |
| Jay Duker | Independent Director | Profile |
Already Invested in Eyepoint Pharmaceuticals?
The danger of trading Eyepoint Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Eyepoint Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Eyepoint Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Eyepoint Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Eyepoint Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Eyepoint Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Eyepoint Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Eyepoint Pharmaceuticals Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyepoint Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Eyepoint Stock analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Eyepoint Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyepoint Pharmaceuticals. If investors know Eyepoint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyepoint Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Revenue Per Share 1.183 | Quarterly Revenue Growth 0.332 | Return On Assets (0.17) | Return On Equity (0.39) |
The market value of Eyepoint Pharmaceuticals is measured differently than its book value, which is the value of Eyepoint that is recorded on the company's balance sheet. Investors also form their own opinion of Eyepoint Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eyepoint Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyepoint Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eyepoint Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyepoint Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyepoint Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyepoint Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.